Pfizer und BioNTech erhalten positive CHMP-Empfehlung für COMIRNATY® bei Kindern von 5 bis unter 12 Jahren in der Europäischen Union
25 nov. 2021 07h30 HE
|
BioNTech SE
NEW YORK, USA und MAINZ, Deutschland, 25. November 2021—Pfizer Inc. (NYSE: PFE, „Pfizer“) und BioNTech SE (Nasdaq: BNTX, „BioNTech“) gaben heute bekannt, dass der Ausschuss für Humanarzneimittel...
Pfizer and BioNTech Receive Positive CHMP Opinion for COMIRNATY® in Children 5 to under 12 Years of Age in the European Union
25 nov. 2021 07h30 HE
|
BioNTech SE
NEW YORK and MAINZ, Germany, November 25, 2021—Pfizer Inc. (NYSE: PFE, “Pfizer”) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) today announced that the Committee for Medicinal Products for Human Use...
Weitere Datenanalyse der Phase-3-Studie bestätigt Sicherheit und hohe Wirksamkeit des Pfizer-BioNTech COVID-19-Impfstoffs bei Jugendlichen im Alter von 12 bis 15 Jahren
22 nov. 2021 06h45 HE
|
BioNTech SE
Der Impfstoff von Pfizer und BioNTech wies in einer weiterführenden Analyse eine 100-prozentige Wirksamkeit gegen COVID-19 auf; es konnten keine schwerwiegenden Sicherheitsbedenken beobachtet...
Follow-Up Data from Phase 3 Trial Of Pfizer-BioNTech COVID-19 Vaccine Support Safety and High Efficacy in Adolescents 12 Through 15 Years of Age
22 nov. 2021 06h45 HE
|
BioNTech SE
Pfizer-BioNTech vaccine demonstrated 100% efficacy against COVID-19 in longer-term analysis, with no serious safety concerns identified Data will support planned submissions for full regulatory...
Arvinas and Pfizer Announce Updated Phase 1 Dose Escalation Data for ARV-471 to be Presented in Spotlight Poster Session at 2021 San Antonio Breast Cancer Symposium
19 nov. 2021 09h55 HE
|
Arvinas Inc.
NEW HAVEN, Conn. and NEW YORK, Nov. 19, 2021 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) and Pfizer Inc. (NYSE: PFE) announced today that updated safety and efficacy data from the Phase 1 dose...
Pfizer and BioNTech Receive Expanded U.S. FDA Emergency Use Authorization of COVID-19 Vaccine Booster to Include Individuals 18 and Older
19 nov. 2021 08h25 HE
|
BioNTech SE
Expanded authorization allows more Americans to receive a booster dose to help preserve a high-level of protection against COVID-19NEW YORK and MAINZ, Germany, November 19, 2021— Pfizer Inc. (NYSE:...
The Consortium for Top-Down Proteomics Launches the Human Proteoform Project
15 nov. 2021 10h17 HE
|
Consortium for Top-Down Proteomics
CAMBRIDGE, Mass., Nov. 15, 2021 (GLOBE NEWSWIRE) -- The Consortium for Top-Down Proteomics today announced the launch of the Human Proteoform Project, with the goal to elucidate the complete set of...
Pfizer und BioNTech erhalten die erste US-Notfallzulassung für COVID-19-Impfung von Kindern im Alter von 5 bis 11 Jahren durch die FDA
29 oct. 2021 17h45 HE
|
BioNTech SE
Die Notfallzulassung (Emergency Use Authorization, „EUA“) basiert auf klinischen Daten, die ein vorteilhaftes Sicherheitsprofil und einen hohen Impfschutz von 90,7 % bei Kindern im Alter von 5 bis 11...
Pfizer and BioNTech Receive First U.S. FDA Emergency Use Authorization of a COVID-19 Vaccine in Children Ages 5 Through 11 Years
29 oct. 2021 17h45 HE
|
BioNTech SE
Emergency Use Authorization (EUA) is supported by clinical data showing a favorable safety profile and high vaccine efficacy of 90.7% in children 5 through 11 years of age during a period when Delta...
Pfizer And BioNTech to Provide U.S. Government an Additional 50 Million Pediatric Doses of COVID-19 Vaccine to Support Further Preparedness for Future Needs
28 oct. 2021 06h58 HE
|
BioNTech SE
Doses expected to be delivered by April 2022 NEW YORK and MAINZ, GERMANY, October 28, 2021 — Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that the U.S. government has...